Ceva Animal Health Acquires Aquilón to Strengthen Swine Intestinal Health Portfolio

Strategic acquisition adds a specialised swine-health biotechnology platform

LIBOURNE, FRANCE / LEÓN, SPAIN — Ceva Santé Animale has acquired Aquilón, a Spanish biotechnology company specialising in research, diagnostics and biological solutions for swine diseases, strengthening its capabilities in intestinal health and preventive veterinary medicine.

Aquilón, founded in 2012 as a spin-off from the University of León, has developed expertise in pig digestive-tract biology, enteric disease diagnostics and vaccine research. The acquisition brings this scientific capability into Ceva’s global animal-health business and adds a vaccine targeting swine dysentery caused by Brachyspira hyodysenteriae.

Financial terms were not disclosed. The companies have not publicly provided the purchase price, Aquilón’s revenue, its valuation, the transaction’s expected earnings contribution or a quantified estimate of cost and revenue synergies.

The strategic significance is nevertheless clear: Ceva is adding a specialised biological product and a research team focused on a defined disease challenge in commercial pig production, rather than simply expanding a conventional distribution portfolio.

Biobhyo: a Vaccine Asset Targeting Swine Dysentery

The principal product associated with the acquisition is Biobhyo, an inactivated vaccine containing B. hyodysenteriae, strain AqDys057. The European Medicines Agency’s Committee for Veterinary Medicinal Products adopted a positive opinion recommending marketing authorisation in June 2025. The product is intended for active immunisation of fattening pigs to reduce the occurrence of dysenteric diarrhoea caused by the bacterium.

The EMA’s assessment described evidence from two studies comparing vaccinated and unvaccinated pigs on commercial farms in two European countries. The vaccination schedules evaluated involved an initial dose at five weeks of age followed by a second dose at eight weeks. The reported benefit was a reduction in dysenteric diarrhoea caused by B. hyodysenteriae.

These findings support the vaccine’s specific indicated purpose. They should not be extrapolated into a claim that vaccination eliminates infection, prevents all causes of diarrhoea, or replaces biosecurity, diagnosis and herd-health management.

Ceva describes the product as the first and only commercial vaccine in Europe against swine dysentery. That wording should be attributed to the company and understood within the relevant regulatory and market context; it is not a claim that the vaccine is authorised or commercially available in every country.

Why swine dysentery matters to the global pork industry

Swine dysentery is a contagious bacterial enteric disease associated with diarrhoea, poor weight gain, weight loss and reduced production efficiency. The disease can impose substantial costs through treatment, delayed finishing, feed inefficiency, veterinary intervention and additional biosecurity measures.

The pathogen is especially relevant in intensive production systems, where animal movement, shared equipment, contaminated environments and inadequate separation between groups can complicate disease control.

The European Medicines Agency has highlighted the potential severity of the disease in infected herds. Such estimates should be interpreted in context: outcomes vary with herd status, pathogen characteristics, management, diagnostic timing and intervention. They should not be treated as universal mortality or infection rates across the global pig population.

The scale of the underlying production sector explains why even incremental improvements in disease prevention matter. US Department of Agriculture Foreign Agricultural Service data put global pork production at approximately 119.8 million metric tonnes for marketing year 2025/26. China accounts for the largest share, followed by the European Union and the United States.

Source: USDA Foreign Agricultural Service. Figures are production estimates, not measurements of swine dysentery prevalence or vaccine demand.

These figures demonstrate the economic scale of pork production, but they cannot be used to calculate Aquilón’s addressable market directly. That would require additional data on disease incidence, herd-level risk, eligible animal populations, product authorisations, vaccination economics and adoption rates.

Research, diagnostics and scientific personnel add strategic value

Aquilón’s significance extends beyond Biobhyo. The company has spent more than a decade conducting applied research into the porcine digestive tract and developing biological approaches to intestinal disease.

The acquisition gives Ceva access to expertise that may support future work in vaccine development, diagnostics and disease-prevention strategies. It also brings a specialised scientific team into a larger animal-health organisation with established veterinary and commercial capabilities.

This creates several potential routes to value:

• Portfolio expansion: adding a differentiated vaccine to Ceva’s swine-health offering.

• Research acceleration: combining Aquilón’s specialised scientific expertise with Ceva’s wider R&D infrastructure.

• Commercial reach: potentially extending the reach of the acquired product through Ceva’s existing country organisations and veterinary relationships, subject to local authorisations.

• Pipeline development: applying the acquired team’s expertise to future biological solutions for enteric disease.

These are strategic possibilities rather than disclosed transaction synergies. Ceva has not published a quantified timetable for new products, projected incremental sales, a research-investment commitment specifically associated with Aquilón, or an earnings forecast attributable to the deal.

Antibiotic stewardship: an important rationale, not an automatic outcome

Ceva has linked the acquisition to disease prevention and reduced reliance on antibiotics. This aligns with a wider veterinary-health priority: preventing bacterial disease can reduce the need for therapeutic intervention when prevention is effective and appropriately implemented.

Swine dysentery can require antimicrobial treatment, and treatment options are constrained by clinical suitability, product authorisation and antimicrobial susceptibility. Disease control therefore depends on more than medicine availability. Veterinary diagnosis, herd biosecurity, cleaning and disinfection, animal movement controls, management practices and surveillance remain essential.

Vaccination can contribute to a prevention-led approach, but the acquisition alone does not demonstrate a measurable reduction in antibiotic use. Such an outcome would need to be established through field data comparing antimicrobial use before and after vaccination, accounting for changes in disease incidence, herd management and other interventions.

For producers and integrators, the relevant economic question is whether a vaccination programme produces a favourable balance between vaccine cost, disease reduction, production performance and the cost of complementary biosecurity measures.